What's actuallyin the vial.

A Certificate of Analysis is an independently produced laboratory document that confirms the identity, purity, and potency of a compound. It is issued by a third-party analytical laboratory, not the manufacturer, not the supplier, and not the seller. That independence is the entire point.

For pharmaceutical compounds, a COA is standard and expected. For peptides sold through legitimate pharmacy channels, it is equally standard. For the grey market, it is almost entirely absent. When a supplier does produce one, it is typically self-issued, which tells you nothing you could not already assume.

Clarve HPLC-tests every peptide at an independent laboratory before any vial is dispensed, and keeps the Certificate of Analysis on file for each one.

High-Performance Liquid Chromatography (HPLC) is the analytical gold standard for verifying the identity and purity of pharmaceutical compounds. It works by separating the components of a sample and measuring each one precisely. The result tells you exactly what is present and in what quantity.

For peptides, HPLC testing confirms two things: identity (that the compound is what it is labelled as) and purity (that the compound contains at least the stated percentage of the active substance, with no significant contamination from related impurities, solvents, or degradation products).

A result of 98%+ pharma grade means that 98% or more of the measurable content is the target peptide. Below 95% is typically considered substandard for pharmaceutical use. Grey market suppliers frequently test at this level or below, and many do not test at all.

Peptides sold through grey market channels, classified as research chemicals and marked not for human use, operate outside the pharmaceutical supply chain entirely. There is no obligation to test, no obligation to disclose results, and no regulatory body with jurisdiction over the product once it leaves the overseas laboratory.

The practical consequences are significant. Independent testing of grey market peptides has found contamination rates and purity shortfalls that would render the same product unsaleable under pharmaceutical standards. A 2021 analysis of research-grade peptides purchased online found that fewer than 40% of samples met pharmaceutical-grade purity thresholds. The remainder ranged from mildly underdosed to contaminated with unidentified substances.

You cannot know what is in a vial without independent testing. A supplier's claim is not a COA. A photograph of a result sheet is not a COA. An independently issued, traceable laboratory document is.

Clarve's compounding pharmacy in Johannesburg tests every peptide at an independent analytical laboratory before dispensing. The result must meet the 98%+ pharma grade threshold. Peptides that fall short are not dispensed.

A Certificate of Analysis is held on file for every peptide in the Clarve catalogue. Independent testing is built into the compounding process, not added as an afterthought.

This is what pharmaceutical-grade compounding looks like. It is not the cheapest way to operate. It is the only accountable way.